(2004; 11 pages)
WHO Pharmaceuticals Newsletter 2004, No. 05
prepared in collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
The aim of this Newsletter is to disseminate information on the safety and efficacy of pharmaceutical products, based on information received from our network of “drug information officers” and other sources such as specialized bulletins and journals, as well as partners in WHO. The information is produced in the form of résumés in English, full texts of which may be obtained on request from:
Quality Assurance and Safety: Medicines, EDM-HTP World Health Organization, 1211 Geneva 27, Switzerland E-mail address: email@example.com Fax: +41 22 791 4730
Further information on adverse reactions may be obtained from the WHO Collaborating Centre for International Drug Monitoring, Stora Torget 3, S-753 20 Uppsala, Sweden Tel: 46-18-65.60.60 Fax: 46-18-65.60.80 E-mail: firstname.lastname@example.org Internet: http://www.who-umc.org prepared in collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
News & Issues
As always, we bring you the latest on drug safety and regulatory information from around the world, for your information and for any action as Member States consider appropriate. We have also included a report on the workshop that was held recently in South Africa as a first step towards introducing Pharmacovigilance in HIV programmes in some African countries.
The 27th Annual meeting of representatives of countries participating in the WHO Programme for International Drug Monitoring was held in Dublin, Ireland this year. Focused surveillance methods, as a complement to spontaneous adverse drug reaction reporting system was the theme of the meeting. The sessions on drugs of current interest as well as the working group exercises were very interesting and stimulating. The recommendations from the working groups will be published in the next issue of the newsletter.
The WHO Advisory Committee on Safety of Medicinal Products (ACSoMP) had its second meeting in October, in Geneva. New issues as well as action taken on previous recommendations were reviewed. A report from this meeting will be published in a later issue of the newsletter.
Many of our readers have expressed an interest in joining the e-list for the newsletter. We have over 400 names on the list now and are happy to include more. You can join the list by writing your e-mail details to email@example.com.